GlassScriptPhysician profile
Diane Chung
NPI 1841773645
$9,477.87
in general payments reported to CMS, 2019-2025
30 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,408 · 2022: $2,002 · 2023: $2,872 · 2024: $1,946 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,560 · Education: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,559.65 |
| Education | $507.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,834.52 | 2021-2025 | |
| Janssen Biotech, INC. | $1,268.22 | 2021-2025 | Tremfya, Simponi, Stelara |
| Amgen INC. | $660.55 | 2021-2025 | Otezla |
| Lilly USA, LLC | $638.54 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $623.30 | 2022-2024 | Sotyktu |
| Ucb, INC. | $587.64 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $486.03 | 2021-2025 | |
| Leo Pharma INC. | $480.12 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $473.37 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Incyte Corporation | $406.86 | 2021-2024 | Opzelura |
| Mayne Pharma Commercial LLC | $339.33 | 2023-2025 | |
| Pfizer INC. | $290.92 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $238.14 | 2021-2024 | Siliq, Targretin, Duobrii |
| Galderma Laboratories, L.P. | $218.04 | 2021-2025 | Aklief |
| Novartis Pharmaceuticals Corporation | $183.18 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $165.12 | 2021-2024 | Dupixent |
| Biofrontera INC. | $129.54 | 2021-2025 | Rhodoled Xl, Xepi, Bf-Rhodoled |
| Dermavant Sciences, INC. | $73.98 | 2023-2024 | Vtama |
| Boston Scientific Corporation | $62.70 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Epi Health, LLC | $58.39 | 2022 | |
| Almirall LLC | $45.27 | 2022-2024 | Seysara |
| Medimetriks Pharmaceuticals, INC. | $39.53 | 2021-2025 | Neo-Synalar |
| Allergan, INC. | $31.93 | 2021 | |
| Journey Medical Corporation | $26.90 | 2022 | |
| Genentech USA, INC. | $23.51 | 2022 | |
| Vyne Pharmaceuticals INC. | $21.55 | 2021 | |
| Organogenesis INC. | $21.16 | 2024 | |
| Sebela Pharmaceuticals INC. | $20.07 | 2022 | |
| Arcutis Biotherapeutics, INC. | $14.82 | 2024 | Zoryve |
| Paratek Pharmaceuticals, INC. | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.